POSTER SESSION III
Tuesday, March 4, 2008 — 9:30 AM - 12:00 Noon
Convention Center Exhibit Hall A
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
GENITOURINARY PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
96
Assessing the Clinical Significance of Limited Cancer in Prostate Needle Biopsies: Correlation with Gland Size May Be the Key
(854)
M Varma, K Edwards, F Ali, DFR Griffiths - University Hospital of Wales, Cardiff, United Kingdom
Do Men with Insignificant Cancer on Radical Prostatectomy Have Predictably Favorable Preoperative Clinical and Biopsy Findings?
(800)
AO Osunkoya, JI Epstein - Emory University School of Medicine, Atlanta, GA; The Johns Hopkins Hospital, Baltimore, MD
Localized Prostate Cancers with Low AMACR Expression Are Associated with an Increased Risk of Prostate Cancer-Specific Death in the Physicians Health Study Cohort
(667)
M Barry, A Eisenstein, S Perner, M Stampfer, L Mucci, M Rubin - Brigham and Women's Hospital, Boston, MA
Detection of Cancer in Radical Prostatectomy Specimens with No Residual Carcinoma in the Initial Specimen
(702)
AS Duffield, JI Epstein - The Johns Hopkins University School of Medicine, Baltimore, MD
Empiric Evaluation of the AJCC TNM Staging System for T1a,b Prostate Cancers
(806)
S Perner, O Andren, K Fall, MA Rubin - Weill Cornell Medical Center, New York, NY; Karolinska Institute, Stockholm, Sweden; Oerebro University Hospital, Oerebro, Sweden
Topographic Characteristics of Clinically Detected Prostate Cancer in Men under Fifty Years of Age Compared to Older Patients: Analysis of Radical Prostatectomy Specimens with Implication for Biopsy Strategies
(722)
H Guan, WA Sakr - Wayne State University, Harper University Hospital, Karmanos Cancer Institute, Detroit, MI
Prostatic Carcinoma in Young Patients: A Detailed Pathologic Study in the Era of Laparoscopic Surgery
(693)
A Contreras, J Taxy, HA Al-Ahmadie - University of Chicago Hospitals, Chicago, IL
Anterior Dominant Prostate Cancer Compared with Posterior Cancers in a PSA Non-Screened Population
(818)
H Samaratunga, B Delahunt, D Duffy, J Yaxley - Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia; Wellington School of Medicine and Health Sciences, Wellington, Otago, New Zealand; Queensland Institute of Medical Research, and Royal Brisbane Hospital, Brisbane, Queensland, Australia
Defining the Anterior Extraprostatic Space: Anatomical Considerations and Clinical Implications
(709)
SW Fine, HA Al-Ahmadie, A Gopalan, SK Tickoo, VE Reuter - Memorial Sloan-Kettering Cancer Center, New York, NY
Transition Zone-Directed Needle Biopsies of the Prostate Uncommonly Sample Clinically Relevant Transition Zone Tumors
(726)
CF Haarer, HA Al-Ahmadie, A Gopalan, SK Tickoo, PT Scardino, VE Reuter, SW Fine - Memorial Sloan-Kettering Cancer Center, New York, NY
How Different Are the Clinicopathologic Features of Predominantly Transition Zone Tumors in Radical Prostatectomies?
(776)
L Meirelles, LLL Freitas, A Billis, LA Magna, U Ferreira - School of Medicine, State University of Campinas (Unicamp), Campinas, SP, Brazil
Renal Angiomyoadenomatous Tumor: Morphologic, Immunohistochemical and Genetic Study of 5 Cases
(732)
O Hes, J Nemcova, R Sima, N Kuroda, S Bulimbasic, M Franco, M Benkovicova, J Kulka, M Hora, M Michal - Charles University Hospital, Plzen, Czech Republic; Red Cross Hospital, Kochi, Japan; University Hospital Dubrava, Zagreb, Croatia; EPM/UNIFESP, Sao Paulo, Brazil; Cytopathos, Bratislava, Slovakia (Slovak Republic); Semmelweis University, Budapest, Hungary
Expression of MDM2 and CDK4 in Angiomyolipomas: A Potential Pitfall in Differential Diagnosis
(789)
AF Nascimento, P Dal Cin, JL Hornick - Brigham and Women's Hospital and Harvard Medical School, Boston, MA
End-Stage Kidney Disease: Gains of Chromosomes 7, 17 and Loss of Y Chromosome in Non-Neoplastic Tissue
(731)
O Hes, R Sima, J Nemcova, M Hora, S Bulimbasic, T Urge, T Reischig, M Dvorak, M Michal - Charles University Hospital, Plzen, Czech Republic; University Hospital Dubrava, Zagreb, Croatia; Charles University, Plzen, Czech Republic
Characterization of Renal Neoplasms Associated with Autosomal-Dominant Polycystic Kidney Disease
(683)
YB Chen, XJ Yang - Weill Cornell Medical College, New York
Sporadic Clear Cell Renal Cell Carcinoma with Diffuse Cytokeratin-7 Immunoreactivity
(672)
C Bicamumpaka, EC Belanger, SJ Robertson, JP Veinot, KT Mai - The Ottawa Hospital, and University of Ottawa, Ottawa, ON, Canada
Clinicopathologic and Immunohistochemical Characteristics of Clear Cell Renal Cell Carcinoma in Relationship to von Hippel-Lindau Gene Status
(664)
H Aydin, L Sercia, T Choueiri, S Vaziri, R Ganapathi, B Rini, R Bukowski, M Zhou - Cleveland Clinic, Cleveland, OH
The Incidence of Lymphoma in Pelvic Lymph Nodes in Patients Undergoing Radical Prostatectomy
(805)
A Perepletchikov, AV Parwani, R Dhir, G Cai, M Yin, S Bastacky - UPMC, Pittsburgh, PA
Clinicopathologic Features of Hematolymphoid Neoplasms Involving the Prostate in Surgical Pathology Specimens at The University of Pittsburgh
(668)
S Bastacky, A Perepletchikov, A Parwani, M Yin, G Cai, R Dhir - UPMC, Pittsburgh, PA
Malignant Profiles in Normal- or Hyperplastic-Appearing Prostate Acini and Ducts
(770)
YG Man, AJ Liu, WA Gardner - Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC; Beijing 301 Hospital, Beijing, China
High Grade Prostatic Intraepithelial Neoplasia-Like Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases
(839)
FR Tavora, JI Epstein - The Johns Hopkins Hospital, Baltimore, MD
Precursor of PSA (Pro-PSA) Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Study of 90 Cases
(768)
J Ma, D Hull, H Singh, K Lang, J Qian, DG Bostwick - Bostwick Laboratories, Glen Allen, VA
High Grade Prostatic Intraepithelial Neoplasia in the Prostatic Central Zone
(673)
C Bicamumpaka, EC Belanger, KT Mai - The Ottawa Hospital, and University of Ottawa, Ottawa, ON, Canada
PTOV-1 Expression Predicts Prostate Cancer in Men with Isolated High-Grade Prostatic Intraepithelial Neoplasia in Needle Biopsy
(697)
I de Torres, S Fernandez, L Alana, R Paciucci, J Morote, S Ramon y Cajal - Foundation Research Institute; Vall de Hebron Hospital and Autonomous University of Barcelona(UAB)Medical School, Barcelona, Spain
Mapping of TMPRSS2-ERG Fusions in the Context of Multi-Focal Prostate Cancer
(711)
B Furusato, CL Gao, L Ravindranath, Y Chen, J Cullen, DG McLeod, S Srivastava, G Petrovics, IA Sesterhenn - Armed Forces Institute of Pathology, Washington, DC; Center for Prostate Disease Research, Bethesda, MD
TMPRSS2-ERG Fusion Prostate Cancer Is a Molecularly Distinct Estrogen-Sensitive Subclass of Aggressive Prostate Cancer
(779)
KD Mertz, SR Setlur, Y Hoshida, F Demichelis, M Lupien, S Perner, A Sboner, Y Pawidan, O Andren, LA Johnson, J Tang, HO Adami, S Calza, AM Chinnaiyan, D Rhodes, S Tomlins, K Fall, LA Mucci, PW Kantoff, MJ Stampfer, SO Andersson, E Varenhorst, JE Johansson, M Brown, TR Golub, MA Rubin - Brigham and Women's Hospital, Boston, MA; The Broad Institute of MIT and Harvard, Cambridge, MA; Dana Farber Cancer Institute, Boston, MA; Yale University, New Haven, CT; Karolinska Institute, Stockholm, Sweden; Oerebro University Hospital, Oerebro, Sweden; Harvard School of Public Health, Boston, MA; University of Michigan Medical School, Ann Arbor, MI; Soeder Hospital, Stockholm, Sweden
Direct Detection of TMPRSS2:ETSfamily Gene Fusion mRNAs in Prostatectomy Tissue: Prevalence and Correlation with Clinicopathologic Data
(780)
S Miick, GY Kwon, C Wixom, P Nigwekar, Y Tadros, R Gupta, HS Robin, MB Amin, H Rittenhouse, J Groskopf - Gen-Probe Incorporated, San Diego, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Sharp Memorial Hospital, San Diego, CA
Prevalence of TMPRSS2-ERG Fusion Prostate Cancer in Men Undergoing Prostate Biopsy in the United States
(786)
JM Mosquera, R Mehra, M Regan, EM Genega, S Gaston, S Perner, M Connor, G Bueti, SA Tomlins, RB Shah, J Wei, M Kearney, LA Johnson, JM Tang, AM Chinnaiyan, MG Sanda, MA Rubin - Brigham and Women's Hosp, Boston, MA; Harvard Med Schl, Boston, MA; Univ of Michigan, Ann Arbor, MI; Beth Israel Deaconess Med Ctr, Boston, MA; Michigan Urology Ctr, Ann Arbor, MI; Comprehensive Cancer Ctr, Ann Arbor, MI; Broad Inst of MIT and Harvard Med Schl, Cambridge, MA; Dana Farber Harvard Comprehensive Cancer Ctr, Boston, MA
MicroRNA Expression in Androgen Independent and Metastatic Prostate Cancer
(669)
O Basturk, J Wei, X Kong, X Zou, Y Peng, J Melamed, P Lee - NYU, New York
Cross-Study Microarray Evaluation of Aggressiveness Factors in Prostate Cancer
(822)
BA Schmitz, AP Marston, SC Schmechel - University of Minnesota, Minneapolis, MN
Incidence of EDNRB Hypermethylation in Prostatic Adenocarcinoma
(670)
DE Baydar, C Himmetoglu, H Ozen, AM De Marzo - Hacettepe University Hospital, Ankara, Turkey; The Johns Hopkins Medical Institutions, Baltimore, MD
Artifactual Mutations in FFPE Tissue Samples: The Case of TP53, EGFR and KLF6 in Prostate Cancer
(653)
L Agell, S Hernandez, S DeMuga, N Juanpere, R Esgueva, M Salido, JA Lorente, A Munne, A Gelabert, S Serrano, J Lloreta - Hospital del Mar, Barcelona, Spain; Pompeu Fabra University, Barcelona, Spain; Autonomous University of Barcelona, Barcelona, Spain
BRAF Mutation Status and Growth Factor Receptor Expression Do Not Predict Baseline Factors or Outcome in Hormone Refractory Prostate Carcinoma
(821)
AJ Schell, I Young, C Hansen, KN Chi, S Taylor - Queen's University, Kingston, ON, Canada; National Cancer Institute of Canada - Clinical Trials Group, Kingston, ON, Canada; BC Cancer Agency, Vancouver, BC, Canada
B-RAF Mutation in Prostatic Carcinoma: A Study of 93 Cases by High-Resolution Melting Amplicon Analysis
(760)
T Liu, C Willmore-Payne, JA Holden, LJ Layfield - University of Utah, Salt Lake City, UT
Elevated Secreted Protein, Acidic, and Rich in Cysteine mRNA Expression in Neoplastic Prostate Epithelial Cells Correlates with PSA Recurrence after Radical Prostatectomy
(712)
B Furusato, CA DeRosa, Y Chen, L Ravindranath, C Cook, J Cullen, DG McLeod, S Srivastava, G Petrovics, IA Sesterhenn - Center for Prostate Disease Research, Rockville, MD; Walter Reed Army Medical Center, Washington, DC; Armed Forces Institute of Pathology, Washington, DC
RNA Interference of HIF-1a Induces PC-3 Prostate Cancer Cell Death by Down-Regulation of the Inhibitor of Apoptosis Protein Family and the Bcl-2 Family Members
(681)
N Chen, R Huang, H Zeng, XQ Chen, YT He, J Gong, Y Huang, Q Zhou - West China Hospital, West China Medical School, Sichuan University, Chengdu, China
Expression of Mammalian Target of Rapamycin and Phosphorylated - mTOR in Prostatic Adenocarcinomas
(740)
BVS Kallakury, GM Sheehan, HAG Fisher, RP Kaufman, Jr., JS Ross - Georgetown University Hospital, Washington, DC; Albany Medical College, Albany, NY
Insulin-Like Growth Factor-1 Receptor Is Up-Regulated in Prostatic Adenocarcinoma and Correlates with Gleason Grade and Stage
(766)
S Lu, JS Ross, TA Jennings, B Mian, HAT Nazeer, CE Sheehan, T Nazeer - Albany Medicval Center, Albany, NY; Albany Medical Center, Albany, NY
PTEN Gene Dosage Affects Downstream AKT Pathway in Hormone Refractory Prostate Cancer
(832)
K Sircar, M Yoshimoto, IH Koumakpayi, G Chen, A Darnell, AG Aprikian, F Saad, TA Bismar, JA Squire - McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; Jewish General Hospital, Montreal, QC, Canada; University of Montreal, Montreal, QC, Canada
Gene Expression Profiles of Ductal Versus Acinar Adenocarcinoma of the Prostate
(820)
S Sanati, MA Watson, AL Salavaggione, PA Humphrey - Washington University School of Medicine, St. Louis, MO
The Likelihood Ratio of Prostatic Carcinoma and Its Relationship to PCA-3 Score
(661)
F Anwar, JR Oppenheimer - Oppenheimer Urologic Reference Lab (OUR Lab), Nashville, TN
Testing a Multigene Model To Predict Lethal Prostate Cancer
(816)
MA Rubin, LA Mucci, Y Pawitan, F Demichelis, K Fall, JR Stark, H-O Adami, S-O Andersson, O Andren, L Holmberg, W Huang, PW Kantoff, R Kim, S Perner, MJ Stampfer, J-E Johansson - Brigham and Women's Hospital, Boston; Harvard School of Public Health, Boston; Karolinska Institutet, Stockholm, Sweden; Orebro University Hospital, Orebro, Sweden; Uppsala University, Uppsala, Sweden; Dana Farber Cancer Institute, Boston
button next to any title to add to Itinerary Planner...
Add
